Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.33 |
| ▸ | CES1 | P23141 | 4/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11034405 | 0.82 | PDE2A (0.32) | CES2CES1PDE2AADRB2ADRB1 | |
| SCHEMBL31621816 | 0.82 | CES2 (0.32) | CES2CES1PDE2AADRB2ADRB1 | |
| SCHEMBL2016761 | 0.80 | EIF4A3 (0.35) | CES2CES1 | |
| SCHEMBL4101136 | 0.79 | CES2 (0.52) | CES2CES1PDE2AADRB2ADRB1 | |
| SCHEMBL2001602 | 0.79 | CES2 (0.52) | CES2CES1PDE2AADRB2ADRB1 | |
| SCHEMBL4099522 | 0.79 | CES2 (0.52) | CES2CES1PDE2AADRB2ADRB1 | |
| SCHEMBL1201615 | 0.78 | CES2 (0.34) | CES2CES1PDE2AADRB2 | |
| SCHEMBL11286520 | 0.78 | CES2 (0.34) | CES2CES1ADRB2 | |
| SCHEMBL7189909 | 0.77 | — | — | |
| SCHEMBL28207987 | 0.77 | ADRB2 (0.36) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-6828467-B2 | Industrial process of the hydrogenolysis of one hydroxyl or methanol group of a fluorinated benzenedimethanol carried out in a solvent in the presence of a catalyst; 2,3,5,6-tetra-fluorobenzyl alcohol from the 4-methyl derivative | SHOWA DENKO K.K. (JP) | 2004-12-07 | — | — | US | claimed |
| EP-1322584-B1 | PROCESS FOR PRODUCING FLUORINATED METHYL-BENZYL ALCOHOL | SHOWA DENKO KK (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20040010167-A1 | Process for producing fluorinated methyl-benzyl alcohol | SHOWA DENKO K.K. (JP) | 2004-01-15 | — | — | US | claimed |
| EP-1322584-A2 | PROCESS FOR PRODUCING FLUORINATED METHYL-BENZYL ALCOHOL | Showa Denko K.K. (JP) | 2003-07-02 | — | — | EP | claimed |
| WO-2002026678-A2 | PROCESS FOR PRODUCING FLUORINATED METHYL-BENZYL ALCOHOL | SHOWA DENKO K.K. (JP) | 2002-04-04 | — | — | WO | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102186921-B | Fluorine-containing copolymer composition and process for production thereof | ASAHI GLASS CO LTD | 2014-01-15 | — | — | CN | disclosed |
| EP-2338935-B1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| CN-102186921-A | Fluorine-containing copolymer composition and process for production thereof | ASAHI GLASS CO LTD | 2011-09-14 | — | — | CN | disclosed |
| US-20110172336-A1 | FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2338935-A1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-06-29 | — | — | EP | disclosed |
| EP-1915331-A2 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | Showa Denko K.K. (JP) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006137348-A2 | PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOL | SHOWA DENKO K.K. (JP) | 2006-12-28 | — | — | WO | disclosed |
| CN-1226258-C | Process for producing fluorinated methyl-benzyl alcohol | SHOWAN DENKO K K (JP) | 2005-11-09 | — | — | CN | disclosed |
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| CN-1466560-A | Process for producing fluorinated methyl-benzyl alcohol | �Ѻ͵繤��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010167-A1 | Process for producing fluorinated methyl-benzyl alcohol | ADH1C, ADH5, ADH1A | CES2 436/4885CES1 808/4885PDE2A 3862/4885 |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CES2 1432/4885CES1 996/4885PDE2A 471/4885 |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CES2 1153/4885CES1 1214/4885PDE2A 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.